Substance P immunoreactivity in Rett syndrome

被引:45
作者
Deguchi, K
Antalffy, BA
Twohill, LJ
Chakraborty, S
Glaze, DG
Armstrong, DD
机构
[1] Texas Childrens Hosp, Dept Pathol, Houston, TX 77030 USA
[2] Rett Ctr, Houston, TX USA
[3] Baylor Coll Med, Houston, TX 77030 USA
[4] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mental Retardat & Birth Defect Res, Kodaira, Tokyo 187, Japan
[5] Kitasato Univ, Sch Med, Dept Pediat, Kanagawa, Japan
关键词
D O I
10.1016/S0887-8994(00)00120-X
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Severe autonomic dysfunction occurs in Rett syndrome (RS), Substance P, a tachykinin peptide that localizes to several brain regions, including the autonomic nervous system, is reduced in the cerebrospinal fluid of patients with RS, The anatomic localization and intensity of substance P immunoreactivity and glial fibrillary acidic protein-positive astrocytes in the brains of 14 patients with RS were compared with those in the brains of 10 age-matched normal patients. Substance P immunoreactivity expression was significantly decreased in RS tissue compared with control tissue in the following regions: dorsal horns, intermediolateral column of the spinal cord, spinal trigeminal tract, solitary tract and nucleus, parvocellular and pontine reticular nuclei, and locus ceruleus, A less significant decrease of substance P immunoreactivity occurred in the substantia nigra, central gray of the midbrain, frontal cortex, caudate, putamen, globus pallidus, and thalamus, Antiglial fibrillary acidic protein-positive astrocytes were increased in the areas in which substance P immunoreactivity was decreased and in other brain regions. Because many of the brain regions with the greatest decrease in substance P immunoreactivity are involved in the control of the autonomic nervous system, especially the solitary tracts and reticular formation, reduced substance P may contribute to the autonomic dysfunction in RS. (C) 2000 by Elsevier Science Inc. All rights reserved.
引用
收藏
页码:259 / 266
页数:8
相关论文
共 28 条
  • [1] Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2
    Amir, RE
    Van den Veyver, IB
    Wan, M
    Tran, CQ
    Francke, U
    Zoghbi, HY
    [J]. NATURE GENETICS, 1999, 23 (02) : 185 - 188
  • [2] Armstrong DD, 1998, NEW DEVELOPMENTS IN CHILD NEUROLOGY, P183
  • [3] BRUSNIKOV GA, 1984, PHARMACOL THERAPEUT, V25, P23
  • [4] CEREBROSPINAL-FLUID STUDIES IN THE RETT SYNDROME - BIOGENIC-AMINES AND BETA-ENDORPHINS
    BUDDEN, SS
    MYER, EC
    BUTLER, IJ
    [J]. BRAIN & DEVELOPMENT, 1990, 12 (01) : 81 - 84
  • [5] CAMPOSCASTELLO J, 1991, PEDIATRICS, V6, P340
  • [6] CHANG MM, 1970, J BIOL CHEM, V245, P4784
  • [7] RETTS SYNDROME - CHARACTERIZATION OF RESPIRATORY PATTERNS AND SLEEP
    GLAZE, DG
    FROST, JD
    ZOGHBI, HY
    PERCY, AK
    [J]. ANNALS OF NEUROLOGY, 1987, 21 (04) : 377 - 382
  • [8] DISTRIBUTION OF SUBSTANCE P-LIKE IMMUNOREACTIVE NEURONS IN THE HUMAN MEDULLA-OBLONGATA - CO-LOCALIZATION WITH MONOAMINE-SYNTHESIZING NEURONS
    HALLIDAY, GM
    LI, YW
    JOH, TH
    COTTON, RGH
    HOWE, PRC
    GEFFEN, LB
    BLESSING, WW
    [J]. SYNAPSE, 1988, 2 (04) : 353 - 370
  • [9] ELEVATED CSF GLUTAMATE IN RETT SYNDROME
    HAMBERGER, A
    GILLBERG, C
    PALM, A
    HAGBERG, B
    [J]. NEUROPEDIATRICS, 1992, 23 (04) : 212 - 213
  • [10] Interactions and coexistence of neuropeptides and serotonin in spinal autonomic systems
    Helke, CJ
    Yang, L
    [J]. NEUROPEPTIDES: BASIC AND CLINICAL ADVANCES, 1996, 780 : 185 - 192